Herpes zoster in the Czech Republic – Epidemiology and Clinical Manifestations
Authors:
J. Smetana 1; M. Salavec 2; V. Boštíková 1; R. Chlíbek 1; P. Boštík 3; I. Hanovcová 1; M. Vacková 1; P. Matulková 1; M. Špliňo 1
Authors‘ workplace:
Katedra epidemiologie, Fakulta vojenského zdravotnictví UO, Hradec Králové
1; Katedra dermatovenerologie, Lékařská fakulta UK Hradec Králové, Klinika nemocí kožních a pohlavních, FN Hradec Králové
2; Centrum pokročilých studií, Fakulta vojenského zdravotnictví UO, Hradec Králové
3
Published in:
Epidemiol. Mikrobiol. Imunol. 59, 2010, č. 3, s. 138-146
Overview
Herpes zoster (shingles) is a viral infection of the skin that manifests itself as painful, unilateral vesicular rash. The causative agent is varicella-zoster virus (VZV). Primary infection with VZV causes chickenpox, a common childhood infection, and then the virus lies dormant in the sensory neural ganglia, reactivating to cause shingles. The most important complications are neurological disorders (in particular postherpetic neuralgia) and eye disorders. First-line therapy are antiviral agents. A single vaccine has been registered to date. Herpes zoster occurs sporadically in the Czech Republic and its incidence is long-term stable. In 1990–2008 the average annual incidence was 6,306 cases (61.3 cases/100 000 population), with the lowest number of 5,511 cases (53.5/100 000) reported in 1991 and the highest number of 6,894 cases (67.6/100 000) reported in 2002. The incidence rate in females (69.9/100 000) was 1.4 times as high as in males (49.5/100 000). From the age perspective, the elderly are at a considerably higher risk of developing shingles. In 2008, the incidence rate was the highest in the age group ≥70 years (155.0/100 000). Nevertheless, the beginning of the upward trend is seen in the age group 45–49 years. Herpes zoster does not show any seasonal trend.
Key words:
herpes zoster – incidence – Czech Republic – clinical manifestations – complications.
Sources
1. Adams, E. N., Parnasy, S., Baptista, P. Herpes zoster and vaccination: a clinical review. Am. J. Health Syst. Pharm., 2010, 1, 67, 9, p. 724–727.
2. Beutner, K. R., Friedman, D. J., Forszpaniak, C. et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob. Agents Chemother., 1995, 39, p. 1547–1553.
3. Cohrs, R. J., Gilden, D. H., Mahalingam, R. Varicella zoster virus latency, neurological disease and experimental models: an update. Front Biosci., 2004, 91, p. 751–762.
4. Cole, N. L., Grose, C. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella/zoster virus. Rev. Med. Virol., 2003, 13, 4, p. 207–222.
5. Crooks, R. J., Jones, D. A., Fiddian, A. P. Zoster-associated chronic pain: an overview of clinical trial with acyclovir. Scand. J. Infect. Dis. Suppl., 1991, 80, p. 62–68.
6. Černý, Z. Changes in the incidence and clinical manifestations of herpes zoster. Čas. Lék. česk., 1996, 135, 8, p. 244–248.
7. Davidson, A. J., Scott, J. E. The complete DNA sequence of varicella-zoster virus. J. Gen. Virol., 1986, 67, p. 1759–1816.
8. Doerr, H. W., Rabenau, H. Dermatotrope Herpesviren. Infektionsbiologie, Epidemiologie und Diagnostik, Chemotherapie, 1996, 1, p. 1–8.
9. Dworkin, R. H., Carrington, D., Cunningham, A. et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral. Res., 1997, 33, p. 73–85.
10. Dworkin, R. H., Portenoy, R. L. Pain and its persistence in Herpes zoster. Pain, 1996, 67, p. 241–251.
11. Gabutti, G., Rota, M. C., Guido, M., Donno, A., Bela, A. et al. The epidemiology of Varicella Zoster Virus infection in Italy. BMC Public Health, 2008, 8, p. 372.
12. Gauthier, A., Breuer, J., Carrington, D., Martin, M., Rémy, V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol. Infect., 2009, 137, 1, p. 38–47.
13. Gibney, M. D., Nahass, G. T., Leonardi, C. L. Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Br. J. Dermatol., 1996, 134, p. 504–509.
14. Gil, A., Gil, R., Alvaro, A., Martín, M., González, A. Burden of herpes zoster requiring hospitalization in Spain dutiny a seven-year period (1998–2004). BMC Infectious Diseases, 2009, 9, p. 55.
15. Gilden, D. Varicella Zoster Virus and Central Nervous System Syndromes. Herpes, 2004, 11, supl. 2, p. 89A–94A.
16. Griffiths, P. D. Herpesviruses and AIDS. J IHMF, 1994, 1, 1, p. 5–11.
17. Gross, G., Schöfer, H., Wassilew, S.W. et al. Herpes zoster guideline of the German Dermatology Society (DDG). J. Clin. Virol., 2003, 26, p. 277–289.
18. Hope-Simpson, R. E. Postherpetic neuralgia. Gen. Pract., 1975, 25, p. 571–575.
19. Huff, J. C., Drucker, J. L., Clemmer, A. et al. Efficacy of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J. Med. Virol., 1993, Suppl. 1, p. 93–96.
20. Chapman, R. S., Cross, K. W., Fleming, D. M. The incidence of shingles and its implications for vaccination policy. Vaccine, 2003, 21, p. 2541–2547.
21. Christo, P. J., Hobelmann, G., Maine, D. N. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging, 2007, 24, p. 1–19.
22. Kilgore, P. E., Kruszon-Moran, D., Seward, J. F. et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J. Med. Virol., 2003, 70, Suppl. 1, p. 111–118.
23. Levin, M. J., Smith, J. G, Kaufhold, R. M., Barber, B. et al. Decline in varicella-zoster virus (VZV) – specific cell-mediated imunity with increasing age and boosting with a high dose VZV vaccine. J. Infect. Dis., 2003, 188, p. 1336–1344.
24. Liesegang, T. J. Varicella zoster viral disease. Mayo Clin. Proc., 1999, 74, p. 983–998.
25. Lilie, H. M., Wassillew, S. W. Varicella-Zoster Virus. Contrib. Microbiol., 1999, 3, p. 111–128.
26. Lungu, O., Annunziato, P. W. Varicella-zoster virus, latency and reactivation. Contrib. Microbiol., 1999, 3, p. 61–75.
27. Malin, J. P. Zoster und Nervensystem. Deutsch. Med. Wochenschr, 1996, 121, p. 635–648.
28. McKendrick, M. W., Care, C., Burke, C. et al. Oral acyclovir in herpes zoster. J. Antimicrob. Chemother., 1984, 14, p. 661–665.
29. Mick, G. Vaccination: a new option to reduce the burden of herpes zoster. Expert Rev. Vaccines, 2010, 9, 3, Suppl., p. 31–35.
30. Opstelten, W., Van Essen, G. A., Schellevis, F., Verheij, T. J. et al. Gender as an independent risk factor for herpes zoster: a population-based prospective. Ann. Epidemiol., 2006, 1006, 16, p. 692–695.
31. Oxman, M. N., Levin, M. J., Johnson, G. R. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med., 2005, 352, p. 2271–2284.
32. Pasqualucci, A., Pasqualucci, V., Galla, F. et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone. Acta Anaesthesiol. Scand., 2000, 44, p. 910–918.
33. Pospíšilová, A. Herpes zoster. Med. Pro Praxi, 2009, 6, 1, p. 38–41.
34. Ragozzino, M. W., Melton, L. J., Kurland, L. T. et al. Population-based study of herpes zoster and its sequelae. Medicine, 1982, 61, p. 310–316.
35. Requena, L., Kutzner, H., Escalonilla, P. et al. Cutaneous reaction at sites of herpes zoster scars: an expanded spectrum. Br. J. Dermatol., 1998, 138, p. 161–168.
36. Roubalová, K., Seman, J. Sérologický přehled protilátek proti herpetickým virům CMV, BV, VZV. Zprávy CEM, 1998, 7, příloha 1, s. 29–31.
37. Rusthoven, J. J., Ahlgren, P., Elhakim, T. et al. Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster. Cancer, 1988, 62, p. 1641–1646.
38. Sauerbrei, A. Virologische und serologische Diagnostik des Herpes zoster. PEG DVV, 2. Konsensus Konferenz zur Therapie und Diagnostik des Herpes zoster, 2002, p. 64–78.
39. Scott, F., Johnson, R., Leedham-Green, M. et al. The burden of herpes zoster: A prospective population based study. Vaccine, 2006, 24, p. 1308–1314.
40. Straus, S. S., Ostrove, J. M., Inchauspé, G. et al. Biology, natural history, treatment and prevention. Ann. Int. Med., 1988, 108, p. 221–237.
41. Suzuki, K., Yoshikawa, T., Tomikata, A., Matsunaga, K., Asano, Y. Detection of aerosolized varicella-zoster virus DNA in patients with localized herpes zoster. J. Infect. Dis., 2004, 189, 6, p. 1009–1012.
42. Thomas, S. L., Hall, A. J. What does epidemiology tell us about risk factors for herpes zoster? Lancet Inf. Dis., 2004, 4, p. 26–33.
43. Van den Broek, P. J., Van der Meer, J. W., Mulder, J. D. et al. Limited value to acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Infection, 1984, 12, p. 338–341.
44. Van Loon, A. M., Van der Logt, J. T., Heessen, F. W., Heeren, M. C. et al. Antibody – capture ELISA that use enzyme-labelled antigen for detection of virus specific IgM, A and G in patients with varicella or herpes zoster. Epidemiol. Infect., 1992, 108, 1, p. 165–174.
45. Vest, C., Munneke, J. A., Smith, R. Herpes zoster oticus: uncommon but recognizable cause of facial paralysis. Postgrad. Med., 1979, 65, p. 143–150.
46. Weaver, B. A. Herpes Zoster Overview: Natural History and Incidence. J. Am. Osteopath. Assoc., 2009, 109, Suppl. 2, p. S2–S6.
47. Weller, T. H., Stoddard, M. B. Intranuclear inclusion bodies in cultures in human tissue inoculated with varicella vesicle fluid. J. Immunol., 1952, 68, p. 311.
48. Whitley, R. J., Gnann, J. W. Herpes zoster: focus on treatment in older adults. Antiviral. Res., 1999, 44, p. 145–154.
49. Whitley, R. J., Weiss, H., Gnann, J. W., Tyring, S., Mertz, G. J. et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann. Intern. Med., 1996, 125, 5, p. 376–383.
50. Wood, M. J., Johnson, R. W., McKendrick, M. W., Taylor, J., Mandal, B. K., Crooks, J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N. Engl. J. Med., 1 1994, 330, 13, p. 896–900.
51. Wood, M. J., Kay, R., Dworkin, R. H. et al. Oral acyclovir therapy accelerates pain resolution in patients with Herpes zoster: a meta-analysis of placebo-controlled trials. Clin. Infect. Dis., 1996, 22, p. 341-347.
52. Wutzler, P., Meister, W. Herpes zoster – Symptomatologie, demographische daten und prognostische faktoren. Dtsch. Ärztebl., 1997, 17, p. 1129–1133.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2010 Issue 3
Most read in this issue
-
Lipophilic Yeasts of the Genus Malassezia and Skin Diseases.
I. Seborrhoeic Dermatitis - Pernicious Anaemia – Diagnostic Benefit of the Detection of Autoantibodies against Intrinsic Factor and Gastric Parietal Cells Antigen H+/K+ ATPase
- Herpes zoster in the Czech Republic – Epidemiology and Clinical Manifestations
- Prevalence of Anti-Epstein-Barr Virus Antibodies in Children and Adolescents with Secondary Immunodeficiency